MiMedx Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 01, 2023 at 04:05 pm EDT
Share
MiMedx Group, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 81.26 million compared to USD 66.88 million a year ago. Net income was USD 1.2 million compared to net loss of USD 10.87 million a year ago.
For the six months, sales was USD 152.93 million compared to USD 125.78 million a year ago. Net loss was USD 3.78 million compared to USD 21.36 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 0.22 a year ago.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
MIMEDX GROUP, INC. 
